Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
Department of Health and Human Services, National Institutes of Health
Forecast: expected to post Mar 1, 2027
Forecast details
- Status
- Forecast: expected to post Mar 1, 2027
- Estimated post date
- Mar 1, 2027
- Estimated application due date
- May 25, 2027
- Estimated award date
- Apr 1, 2028
- Estimated project start
- Apr 1, 2028
- Fiscal year
- 2028
- Forecast posted
- Sep 23, 2026
- Funding opportunity number
- RFA-NS-28-009
- Grants.gov ID
- 363926
- Funding instrument
- Cooperative Agreement
- Category of funding
- Health
- Opportunity category
- Discretionary
- Award ceiling
- Not stated
- Award floor
- Not stated
- Total program funding
- Not stated
- Expected awards
- Not stated
- Cost sharing required
- No
- Assistance Listing (ALN/CFDA)
- 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders
Who can apply
Businesses are among the eligible applicants listed on Grants.gov.
- Public and State controlled institutions of higher education
- State governments
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- County governments
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- Native American tribal organizations (other than Federally recognized tribal governments)
- Special district governments
- For profit organizations other than small businesses
- City or township governments
- Native American tribal governments (Federally recognized)
Additional information on eligibility
Eligible applicants must be clinical trial sites that participate in a phase 2/3 or phase 3 efficacy clinical trial (designed to provide pivotal data to establish substantial evidence of effectiveness in support of a marketing application) supported by a U.S. based small business concern that is the FDA-designated sponsor of a drug or biological product which is the subject of an IND under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) to prevent, diagnose, mitigate, treat, or cure ALS. The definition of a small business concern can be found in section 3(a) of the Small Business Act (15 U.S.C. 632(a)).Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
This product uses the Grants.gov API but is not endorsed or certified by the U.S. Department of Health and Human Services.
Description
Announcement and documents
No attachments listed in the Grants.gov data. Check the official listing for documents.
Grantor contact
The agency contact for this forecast is listed on the official Grants.gov forecast. We don't copy personal contact details from forecasts.
Grants: Grants.gov (federal grant opportunities) · last updated Nov 20, 2026, 4:20 PM ET.
This product uses the Grants.gov API but is not endorsed or certified by the U.S. Department of Health and Human Services.
Always confirm details, amendments and deadlines on the official listing. Government Bid Finder is an independent service and is not affiliated with or endorsed by the U.S. government.